Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Beyond Progressive Disease: A Retrospective Analysis for Japanese Patients with Activating EGFR Mutations
暂无分享,去创建一个
A. Kubo | S. Kudoh | M. Takada | Y. Matsuda | K. Asami | T. Kawaguchi | A. Tamiya | S. Atagi | T. Okuma | N. Takeuchi | K. Okishio | K. Nishie | N. Omachi | T. Mimori | Y. Maruyama
[1] P. Jänne,et al. Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[3] S. Kudoh,et al. 9118 POSTER Prospective Assesment of Combined Pemetrexed and Erlotinib or Gefitinib Therapy After the Relapse to Erlotinib or Gefitinib in Patients With Advanced Non-Small Cell Lung Cancer Having an Active Epidermal Growth Factor Receptor Mutation , 2011 .
[4] C. Sima,et al. Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design , 2011, Clinical Cancer Research.
[5] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[6] S. Digumarthy,et al. Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors , 2011, Science Translational Medicine.
[7] M. Kris,et al. Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib , 2011, Clinical Cancer Research.
[8] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[9] A. Vincent-Salomon,et al. Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study , 2010, The oncologist.
[10] Thomas J. Smith,et al. 美国临床肿瘤学会Ⅳ期非小细胞肺癌化疗的临床实践指南更新 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.
[11] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[12] M. Kris,et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] Thomas J. Smith,et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Y. Ichinose,et al. Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer. , 2009, Anticancer research.
[15] A. Gemma,et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Y. Ohe,et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] D. Sargent,et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE). , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] S. Lippman,et al. Lung cancer. , 2008, The New England journal of medicine.
[19] William Pao,et al. Prospective Assessment of Discontinuation and Reinitiation of Erlotinib or Gefitinib in Patients with Acquired Resistance to Erlotinib or Gefitinib Followed by the Addition of Everolimus , 2007, Clinical Cancer Research.
[20] W. Ajiki,et al. Cancer incidence and incidence rates in Japan in 2002: based on data from 11 population-based cancer registries. , 2006, Japanese journal of clinical oncology.
[21] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[22] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[23] L. Tanoue. Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .
[24] Lin Huan,et al. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[25] L. Tanoue,et al. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma , 2010 .
[26] L. Tanoue. Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .
[27] N. Hanna,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .
[28] H. Wanebo,et al. Soft tissue sarcoma. , 1997, Medicine and health, Rhode Island.
[29] N. Dubrawsky. Cancer statistics , 2022 .